These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 26630316

  • 1. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E, Rayess N, Ho AC, Regillo CD.
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravitreal anti-vascular endothelial growth factor for typical exudative age-related macular degeneration in eyes with good baseline visual acuity.
    Chang YS, Han JI, Yoo SJ, Lew YJ, Kim JH.
    Korean J Ophthalmol; 2014 Dec; 28(6):466-72. PubMed ID: 25435749
    [Abstract] [Full Text] [Related]

  • 6. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen.
    Rayess N, Houston SK, Gupta OP, Ho AC, Regillo CD.
    Am J Ophthalmol; 2015 Jan; 159(1):3-8.e1. PubMed ID: 25217859
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
    Houston SK, Rayess N, Cohen MN, Ho AC, Regillo CD.
    Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
    [Abstract] [Full Text] [Related]

  • 9. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
    Arnold JJ, Campain A, Barthelmes D, Simpson JM, Guymer RH, Hunyor AP, McAllister IL, Essex RW, Morlet N, Gillies MC, Fight Retinal Blindness Study Group.
    Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
    Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.
    Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL.
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E, Katz G, Moisseiev J, Loewenstein A, Goldstein M, Lomnicky Y, Abend Y, Treister G, Goldenberg D, Levkovitch-Verbin H.
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [Abstract] [Full Text] [Related]

  • 17. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS.
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [Abstract] [Full Text] [Related]

  • 18. EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.
    Rahimy E, Ying GS, Pan W, Hsu J.
    Retina; 2019 Apr; 39(4):636-647. PubMed ID: 29517580
    [Abstract] [Full Text] [Related]

  • 19. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
    Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, Okada AA, Iida T.
    Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
    [Abstract] [Full Text] [Related]

  • 20. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L, Krohn J.
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.